Moxonidin Teva (Moxonidine)

Moxonidine selectively stimulates imidazoline I1 receptors in the brainstem, which reduces sympathetic nervous system outflow. This leads to decreased peripheral vascular resistance, lower heart rate, and reduced renin release, collectively lowering arterial blood pressure.

The appropriate dose of Moxonidine is determined by the prescribing clinician based on the individual’s blood‑pressure response, renal function, and overall health status. Dosage may be adjusted during therapy to achieve optimal control.

Safety data for Moxonidine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Moxonidine belongs to the imidazoline receptor agonist class, offering a central mechanism distinct from beta‑blockers, ACE inhibitors, or calcium‑channel blockers. It tends to produce less reflex tachycardia than some alternatives and can be combined with other antihypertensives for additive effect.

Moxonidine tablets should be stored at ambient temperature below 25 °C, in the original container, protected from moisture and light. Keep out of reach of children and do not use after the expiry date.

Moxonidine is taken orally as a tablet. It may be swallowed whole with a glass of water, with or without food, as directed by the prescriber. Consistency in timing each day helps maintain stable blood‑pressure control.

Serious adverse events include severe hypotension, bradycardia, allergic skin reactions, significant liver enzyme elevations, cardiac arrhythmias, and syncope. Patients should seek immediate medical attention if they experience any of these symptoms.

Moxonidine is contraindicated in individuals with known hypersensitivity to the drug, severe hepatic impairment, or in patients where a marked reduction in blood pressure could be hazardous. Clinicians should also exercise caution in patients with advanced renal disease.